{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:00:20Z","timestamp":1787792420482,"version":"build-2784847793"},"reference-count":73,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) is a preventable, progressive disease and the third leading cause of death worldwide. The epidemiological data of COPD from Gulf countries are very limited, as it remains underdiagnosed and underestimated. Risk factors for COPD include tobacco cigarette smoking, water pipe smoking (Shisha), exposure to air pollutants, occupational dusts, fumes, and chemicals. Inadequate treatment of COPD leads to worsening of disease. The 2024 GOLD guidelines recommend use of inhaled bronchodilators, corticosteroids, and adjunct therapies for treatment and management of COPD patients based on an individual assessment of the severity of symptoms and risk of exacerbations. This article reviews COPD pharmacotherapy in the Gulf countries and explores the role of nebulization in the management of COPD in this region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To review the COPD pharmacotherapy in the Gulf Countries, literature search was conducted using PubMed, Medline, Cochrane Systematic Reviews, and Google Scholar databases (before December 2022), using search terms such as COPD, nebulization, inhalers\/inhalation, aerosols, and Gulf countries. Relevant articles from the reference list of identified studies were reviewed. Consensus statements, expert opinion, and other published review articles were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the Gulf countries, pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers, and nebulizers are used for drug delivery to COPD patients. pMDIs and DPIs are most prone to errors in technique and other common device handling errors. Nebulization is another mode of inhalation drug delivery, which is beneficial in certain patient populations such as the elderly and patients with cognitive impairment, motor or neuromuscular disorders, and other comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is no major difference between Gulf countries and rest of the world in the approach to management of COPD. Nebulizers should be considered for patients who have difficulties in accessing or using MDIs and DPIs, irrespective of geographical location.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2023.0016","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T08:28:56Z","timestamp":1717057736000},"page":"189-201","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence and Management of Chronic Obstructive Pulmonary Disease in the Gulf Countries with a Focus on Inhaled Pharmacotherapy"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5607-4872","authenticated-orcid":false,"given":"Donald P.","family":"Tashkin","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA Health Sciences, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Barjaktarevic","sequence":"additional","affiliation":[{"name":"Department of Medicine, UCLA, Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Gomez-Seco","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Fakeeh University Hospital, Dubai, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser Hassan","family":"Behbehani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kuwait University, Kuwait, Kuwait."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkady","family":"Koltun","sequence":"additional","affiliation":[{"name":"Viatris, Inc., Canonsburg, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj Alam","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Viatris, Inc., Dubai, United Arab Emirates."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061225"},{"key":"e_1_3_5_3_2","unstructured":"World Health Organization. Chronic Obstructive Pulmonary Disease (COPD): Key Facts. 2022. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd) [Last accessed: August 4 2022]."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.26719\/emhj.18.014"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S234942"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268772"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30105-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.4103\/HMJ.HMJ_27_19"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(12)70010-0"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(12)70012-4"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(12)70011-2"},{"key":"e_1_3_5_12_2","first-page":"273","article-title":"Comorbidities associated with COPD in the Middle East and North Africa region: association with severity and exacerbations","volume":"11","author":"Mahboub B","year":"2016","unstructured":"Mahboub B, , Alzaabi A, , Iqbal MN, et al. Comorbidities associated with COPD in the Middle East and North Africa region: association with severity and exacerbations. Int J Chron Obstruct Pulmon Dis. 2016; 11:273\u2013280.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(12)70013-6"},{"key":"e_1_3_5_14_2","doi-asserted-by":"crossref","unstructured":"Mohammad Y Waked M Hamzaoui A. Chronic Respiratory Diseases in the Arab World. Handbook of Healthcare in the Arab World: Springer Nature; Switzerland AG; 2021; pp. 2767\u20132806.","DOI":"10.1007\/978-3-030-36811-1_127"},{"issue":"2","key":"e_1_3_5_15_2","first-page":"1","article-title":"Review of COPD in Middle East and Gulf countries","volume":"7","author":"Alzaabi A.","year":"2019","unstructured":"Alzaabi A. Review of COPD in Middle East and Gulf countries. Med Res Arch, 2019; 7(2):1\u201313.","journal-title":"Med Res Arch"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/atm.atm_639_20"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S26350"},{"issue":"4","key":"e_1_3_5_18_2","first-page":"210","article-title":"Canadian Thoracic Society Clinical Practice Guideline on Pharmacotherapy in Patients with COPD\u20132019 Update of Evidence","volume":"3","author":"Bourbeau J","year":"2019","unstructured":"Bourbeau J, , Bhutani M, , Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on Pharmacotherapy in Patients with COPD\u20132019 Update of Evidence. Can J Res Critical Care Sleep Med, 2019; 3(4):210\u2013232.","journal-title":"Can J Res Critical Care Sleep Med"},{"key":"e_1_3_5_19_2","unstructured":"Service NH. Chronic Obstructive Pulmonary Disease (COPD). 2019. Available from: https:\/\/www.nhs.uk\/conditions\/chronic-obstructive-pulmonary-disease-copd\/treatment [Last accessed: August10 2022]."},{"key":"e_1_3_5_20_2","unstructured":"GOLD Guidelines Committees. Global Strategy for the Diagnosis Management and Prevention of Chronic Obstructive Pulmonary Disease. 2024 Report [Internet]; 2024. Available from: https:\/\/goldcopd.org\/2024-gold-report [Last accessed: January10 2024]."},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60926-9"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/1817-1737.128843"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2011.630047"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp012477"},{"issue":"1","key":"e_1_3_5_25_2","first-page":"CD003900","article-title":"Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease","volume":"2010","author":"McCrory DC","year":"1996","unstructured":"McCrory DC, , Brown CD, , Group CA. Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst, 1996; 2010(1):CD003900.","journal-title":"Cochrane Database Syst"},{"issue":"1","key":"e_1_3_5_26_2","article-title":"Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease [Intervention Review]","volume":"2010","author":"Ram FS","year":"1996","unstructured":"Ram FS, , Brocklebank DD, , Muers M, et al. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease [Intervention Review]. Cochrane Database Syst Rev; 1996; 2010(1):CD002170:1\u201323.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.033266"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.17.2301"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.4.957"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1058154"},{"issue":"7","key":"e_1_3_5_31_2","first-page":"CD009285","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"2014","author":"Karner C","year":"2014","unstructured":"Karner C, , Chong J, , Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2014; 2014(7):CD009285.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008378"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70158-9"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S2389"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.809"},{"key":"e_1_3_5_36_2","unstructured":"NICE. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. National Institute for Health and Care and Excellence (NICE) Guideline. 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ng115\/resources\/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245 [Last accessed: July20 2022]."},{"key":"e_1_3_5_37_2","unstructured":"GSK. Trelegy Ellipta: Fluticasone Furoate Umeclidinium Vilanterol. 2023. Available from: https:\/\/www.trelegy.com [Last accessed: October1 2023]."},{"key":"e_1_3_5_38_2","unstructured":"AztraZeneca. Breztri Aerosphere: Budesonide Glycopyrrolate Formeterol Fumarate. 2023. Available from: https:\/\/www.breztri.com [Last accessed: October1 2023]."},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753466620942128"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105938"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1555610"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556058"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S252435"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S114034"},{"key":"e_1_3_5_45_2","unstructured":"Sunovion. Lonhala\u00ae Magnair\u00ae (Glycopyrrolate) Inhalation Solution Highlights of Prescribing Information. 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208437Orig1s000lbl.pdf [Last accessed June20 2022]."},{"key":"e_1_3_5_46_2","unstructured":"L.P. MS. YUPELRI\u00ae (Revefenacin) Inhalation Solution. Highlights of Prescribing Information. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210598s001lbl.pdf [Last accessed: March10 2022]."},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70187-5"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S178951"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.594123"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S117196"},{"key":"e_1_3_5_51_2","first-page":"23","article-title":"Considerations for managing chronic obstructive pulmonary disease in the elderly","volume":"9","author":"Taffet GE","year":"2014","unstructured":"Taffet GE, , Donohue JF, , Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. Clin Interv Aging, 2014; 9:23\u201330.","journal-title":"Clin Interv Aging"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S32674"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.01.005"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.10.008"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.335"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05501313"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.01.006"},{"key":"e_1_3_5_58_2","first-page":"145","article-title":"Development of Respimat((R)) Soft Mist Inhaler and its clinical utility in respiratory disorders","volume":"4","author":"Dalby RN","year":"2011","unstructured":"Dalby RN, , Eicher J, , Zierenberg B. Development of Respimat((R)) Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl), 2011; 4:145\u2013155.","journal-title":"Med Devices (Auckl)"},{"key":"e_1_3_5_59_2","doi-asserted-by":"crossref","unstructured":"Deb PK Abed SN Maher H et al. Aerosols in Pharmaceutical Product Development. Drug Delivery Systems: Academic Press: Cambridge Massachusetts; 2020; pp. 521\u2013577.","DOI":"10.1016\/B978-0-12-814487-9.00011-9"},{"key":"e_1_3_5_60_2","article-title":"2022 GINA Main Report: Global Strategy for Asthma management and Prevention","author":"Global Initiative for Asthma","year":"2022","unstructured":"Global Initiative for Asthma. 2022 GINA Main Report: Global Strategy for Asthma management and Prevention. GINA, 2022; Available from: GINA Main Report 2022 Front Cover (ginasthma.org) [Last accessed: September 15, 2022].","journal-title":"GINA"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.026"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00390"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105857"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.4081\/mrm.2017.236"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1177\/1479973119901234"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2017.1365120"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753466619884532"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-017-0016-z"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.05803"},{"key":"e_1_3_5_70_2","first-page":"88","article-title":"The efficacy and safety of nebulization treatments for chronic obstructive pulmonary disease","volume":"7","author":"Tashkin DP.","year":"2011","unstructured":"Tashkin DP. The efficacy and safety of nebulization treatments for chronic obstructive pulmonary disease. US Respir Dis, 2011; 7:88\u201392.","journal-title":"US Respir Dis"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.09540754"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.5152\/ejp.2014.00087"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.5.7952549"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2001.1292"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2023.0016","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2023.0016","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2023.0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:32Z","timestamp":1777644692000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2023.0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8,1]]}},"alternative-id":["10.1089\/jamp.2023.0016"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2023.0016","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}